GENinCode Plc (AIM: GENI)

Market Cap	11.95M
Revenue (ttm)	2.16M
Net Income (ttm)	-7.02M
Shares Out	176.96M
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	46,119
Open	7.00
Previous Close	6.75
Day's Range	6.55 - 7.00
52-Week Range	3.34 - 12.50
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 16, 2024

About GENinCode

GENinCode Plc develops and commercializes clinical genetic tests to provide predictive analysis of risk to a patient’s health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company’s molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a patented genetic test to help user to adopt cardiovascular pr...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2018
• Employees: 42
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: GENI

Financial Performance

In 2023, GENinCode's revenue was 2.16 million, an increase of 51.05% compared to the previous year's 1.43 million. Losses were -7.02 million, 26.2% more than in 2022.